Fifteen-year clinical review demonstrates eye preservation via intra-arterial chemotherapy in retinoblastoma, highlighting reduced systemic toxicity.
Since its introduction in 2008, intra-arterial chemotherapy (IAC) has significantly improved the conservative (eye preserving) management of retinoblastoma (rb), allowing not only the salvage of eyes that would otherwise face enucleation, but also, together with intravitreal chemotherapy, to eradicate the need for external beam irradiation [1]. The success of IAC lies in the achievement of high-dose concentrations of chemotherapy agents directly into the blood vessels that supply the eye, while reducing systemic exposure and complications of intravenous chemotherapy (IVC) such as hospitalizations, port placement, and frequent need for transfusions [2], [3].
No takes yet. Share an insight, caveat, or question.
Stathopoulos et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: